Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bailing Anshen is a Traditional Chinese Medicine (TCM) formulation developed by Shijiazhuang Yiling Pharmaceutical for the treatment of insomnia. It is specifically indicated for patients presenting with the TCM syndrome of deficiency of heart blood and kidney essence. The drug has undergone Phase III clinical evaluation in China (CTR20130942) to assess its efficacy and safety in improving sleep quality. As a TCM product, its mechanism involves multi-target regulation to nourish the heart, tonify the kidney, and soothe the nerves, addressing the underlying systemic imbalances associated with sleep disturbances in the TCM framework.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bailing Anshen.